Invest now

Anthem BioSciences share price

Balanced risk
  • 28%Low risk
  • 28%Moderate risk
  • 28%Balanced risk
  • 28%High risk
  • 28%Extreme risk
  • ₹966.30(0.77%)
    November 11, 2026 09:49:13 AM IST
    • NSE
    • BSE
  • Vol : 83.22 K (NSE + BSE)
    Last 20 day avg : 583.63 K
Anthem BioSciences is trading 0.77% upper at Rs 966.30 as compared to its last closing price. Anthem BioSciences has been trading in the price range of 971.25 & 956.65. Anthem BioSciences has given 47.07% in this year & 12.14% in the last 5 days. Anthem BioSciences has TTM P/E ratio 78.70 as compared to the sector P/E of 45.29.There are 3 analysts who have initiated coverage on Anthem BioSciences. There are 0.00 analysts who have given it a strong buy rating & 2 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 211.46 Crores in its last quarter.Listed peers of Anthem BioSciences include Sun Pharmaceutical Industries (-0.31%), Divi's Laboratories (-1.66%), Torrent Pharmaceuticals (-0.11%).The Mutual Fund holding in Anthem BioSciences was at 9.25% in 30 Sep 2026. The MF holding has increased from the last quarter. The FII holding in Anthem BioSciences was at 3.79% in 30 Sep 2026. The FII holding has increased from the last quarter.
  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Loading...
Key Metrics

Updated on 11 Nov 2026, 09:59 AM IST

  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.02
    Lower than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.21
    Lower than industry
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    5.88
    Indicates overvaluation
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    -
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    -
  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    -
Price range
Day Range
Lowest
956.65
Highest
971.25
52 week range
Lowest
579.45
Highest
989.15
Anthem BioSciences Peers
Return Comparison
Peers Comparison
Names
Price%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Sun Pharmaceutical Industries
1,899.10-0.314,55,646.9738.405.550.830.47
Divi's Laboratories
11,377.75-1.663,02,043.5173.3211.480.410.03
Torrent Pharmaceuticals
4,769.80-0.111,81,421.3772.7319.220.80141.16
Cipla
1,413.100.501,14,158.4727.573.330.921.11
Zydus Lifesciences
1,202.45-0.871,19,944.8521.194.240.0914.22
Anthem BioSciences Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2026-11-03Quarterly Results
2026-07-21Quarterly Results
2026-05-19Audited Results & Final Dividend
2026-02-05Quarterly Results
2025-11-08Quarterly Results
About the company Anthem BioSciences
  • IndustryBiotechnology & Drugs
  • ISININE0CZ201020
  • BSE Code544449
  • NSE CodeANTHEM
Anthem Biosciences Limited is an India-based contract research, development and manufacturing organization (CRDMO) with fully integrated operations spanning across drug discovery, development and manufacturing. The Company’s segments include CRDMO and Speciality Ingredients. The Company helps new and established biotech’s and big pharma, develop, optimize and test proteins, monoclonal antibodies, peptides, large molecules, small molecules, toxins and others. In addition to product research and development, it helps test drugs for safety, efficacy (in vitro and in vivo), pre-clinical animal studies in a GLP facility, clone development, antibody drug conjugates, research and development and manufacture of highly potent compounds, flow chemistry-based production and large-scale commercial product manufacture. Its CRDMO Services include Large Molecules, Small Molecules, HPAPI, Peptides, Lipids, ADCs and Oligonucleotides.
  • Management Info
  • Ajay BhardwajChief Executive Officer, Managing Director (Promoter)
  • Mohammed Gawir BaigChief Financial Officer
  • K ChandrappaWhole Time Director, Chief Operating Officer
  • Divya PrasadCompliance Officer, Company Secretary
Anthem BioSciences Share Price FAQs

Anthem BioSciences is trading at 966.30 as on Wed Nov 11 2026 04:19:13. This is 0.77% upper as compared to its previous closing price of 958.90.

The market capitalization of Anthem BioSciences is 54453.72 Cr as on Wed Nov 11 2026 04:19:13.

The average broker rating on Anthem BioSciences is Buy. The breakup of analyst rating is given below -

  • 0.00 analysts have given a strong buy rating
  • 2 analysts have given a buy rating
  • 1 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Anthem BioSciences is 989.15 whereas the 52 wk low is 579.45

Anthem BioSciences can be analyzed on the following key metrics -

  • TTM P/E: 78.70
  • Sector P/E: 45.29
  • Dividend Yield: 0.21%
  • D/E ratio: 0.01

Anthem BioSciences reported a net profit of 591.79 Cr in 2026.

The Mutual Fund Shareholding was 9.25% at the end of 30 Sep 2026.